In this webinar we will cover the recent manufacturer restrictions in the 340B market, including the latest legal updates, new restrictions, and lessons learned that will help covered entities navigate this new landscape.
The current state and most recent development of the 20+ manufacturers that have joined the group who removed 340B drug access for CEs
how to quickly analyze effect on CEs access and financials
review the process for submission with each step to avoid common pitfalls
common post data submission challenges and steps CEs can take to not lose pricing once provided
unique challenges with wholesalers, gateways, and chain pharmacies that could lead to missed savings